Not waving but drowning: Takeda’s blood cancer drug flunks phase 3, dealing further blow to hopes of approval flurry
Not waving but drowning: Takeda’s blood cancer drug flunks phase [...]
Disc Medicine nabs $90M for blood disease pipeline, new Roche asset
Disc Medicine nabs $90M for blood disease pipeline, new Roche [...]
After one HBV flop, Assembly Biosciences forced to drop a hepatitis asset amid safety woes
After one HBV flop, Assembly Biosciences forced to drop a [...]
Exit of Avidity CMO on cusp of first clinical trial sparks stock rout
Exit of Avidity CMO on cusp of first clinical trial [...]
HebeCell lands $53M, Chinese collaborator to make a splash in busy CAR-NK space
HebeCell lands $53M, Chinese collaborator to make a splash in [...]
After cutting dose because of deaths, Astellas pauses gene therapy trial as new liver issue arises
After cutting dose because of deaths, Astellas pauses gene therapy [...]
J&J’s HIV vaccine fails phase 2b, extending long wait for an effective jab
J&J’s HIV vaccine fails phase 2b, extending long wait for [...]
GSK, Korean biotech SK go head-to-head against AstraZeneca’s COVID-19 shot with their experimental vaccine
GSK, Korean biotech SK go head-to-head against AstraZeneca’s COVID-19 shot [...]
A year after a death and accompanying trial hold, Poseida hopes for reprieve with early solid tumor CAR-T data
A year after a death and accompanying trial hold, Poseida [...]
The descent of van de Stolpe: Galapagos CEO exits after R&D setbacks wipe out billions in value
The descent of van de Stolpe: Galapagos CEO exits after [...]